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Background: Patients treated for a thoracic malignancy carry a significant risk of developing other lung lesions.
Locoregional control of intrathoracic recurrences is challenging due to the impact of prior therapies on normal
tissues. We examined the safety and efficacy of thoracic re-irradiation using high-precision image-guided
stereotactic body radiation therapy (SBRT).
Methods: Records of 39 patients with prior intra-thoracic conventionally fractionated radiation therapy (RT) who
underwent SBRT for a subsequent primary, recurrent or metastatic lung tumor from 11/2004 to 7/2011 were
retrospectively reviewed.
Results: Median dose of prior RT was 61 Gy (range 30–80 Gy). Median biologically effective prescription dose
(α/β = 10) (BED10) of SBRT was 70.4 Gy (range 42.6-180 Gy). With a median followup of 12.6 months among
survivors, 1- and 2-year actuarial local progression-free survival (LPFS) were 77% and 64%, respectively. Median
recurrence-free (RFS) and overall survival (OS) were 13.8 and 22.0 months, respectively. Patients without overlap of
high-dose regions of the primary and re-irradiation plans were more likely to receive a BED10 ≥100 Gy, which was
associated with higher LPFS (hazard ratio, [HR] = 0.18, p = 0.04), RFS ([HR] = 0.31, p = 0.038) and OS ([HR] = 0.25,
p = 0.014). Grade 2 and 3 pulmonary toxicity was observed in 18% and 5% of patients, respectively. Other grade
2–4 toxicities included chest wall pain in 18%, fatigue in 15% and skin toxicity in 5%. No grade 5 events occurred.
Conclusions: SBRT can be safely and successfully administered to patients with prior thoracic RT. Dose reduction
for cases with direct overlap of successive radiation fields results in acceptable re-treatment toxicity profile.
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Thoracic re-irradiation is not uncommonly encountered
in the clinic as a considerable number of patients with
primary or metastatic lung lesions require repeat treat-
ments to the thorax for recurrent or metachronous dis-
ease. Lung cancer remains the second most common
malignancy in the U.S. with an estimated 221,130 new
cases diagnosed in 2011, and as many as 61% of all lung
cancer patients receive radiotherapy (RT) at initial pres-
entation [1]. Although the majority of relapses are sys-
temic, a considerable percentage is limited to the thorax,
which represents a subset of patients who may benefit* Correspondence: rimnera@mskcc.org
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reproduction in any medium, provided the orfrom local therapy. Early-stage patients have a 4–10%
chance of developing a metachronous second lung
tumor in the first 5 years after treatment [2-4]. Patients
with stage III non-small cell lung cancer (NSCLC)
treated with concurrent chemoradiation have a 25% risk
of isolated locoregional failure within the radiation field
[5]. In addition, the lungs are a common site for metas-
tases from other malignancies, where local therapy to
the thorax may be indicated for palliation of symptoms.
Re-irradiation of the thorax for recurrent lung cancer
with conventionally fractionated RT has yielded 1-year
local progression-free (LPFS) and overall survival (OS)
of up to 51% and 59%, respectively [6-10]. Image-guided
hypofractionated stereotactic body radiation therapy
(SBRT) is a useful modality for repeat treatments be-
cause it allows for delivery of high radiation dose to theral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sue. SBRT has been shown to be highly effective in the
treatment of small lung lesions including early-stage
lung cancer [11,12] as well as pulmonary metastasis
[13-15]. A number of different fractionation schemes
have been used. Their relative biological effectiveness
can be approximated using a widely accepted formula of
biologically equivalent dose (BED), where the alpha beta
ratio (α/β) is a radiosensitivity parameter unique to each
tumor tissue and outcome, and is commonly set to 10
for lung tumor control and acute toxicity. SBRT frac-
tionation schemes with BED for α/β = 10 (BED10) ≥100
Gy were associated with improved outcomes [11]. How-
ever, the efficacy and risk of SBRT in the setting of re-
irradiation is not well characterized. Kelly et al. recently
described their experience with SBRT after prior conven-
tionally fractionated RT in 36 patients [16]. They pre-
dominantly employed 50 Gy in 4 fractions and reported
excellent 2-year local control (LC), progression-free sur-
vival (PFS) and OS rates of 95%, 26% and 59% respect-
ively, although at the expense of a 64% rate of grade 2–3Table 1 Patient characteristics at the time of SBRT
Patient characteristics at the time of SBRT
Median age, years (range) 71 (41–94)




History of tobacco use, N (%) 39 (100%)
COPD, N (%) 22 (56%)
Median follow-up, months (range) 12.6 (1.3-47.5)
Median interval between fractionated RT and SBRT,
months (range)
37 (1–180)




Median prior radiation dose, Gy (range) 61 (30–80)
History of thoracic surgery, N (%) 21 (54%)
History of chemotherapy, N (%) 22 (56%)
Diagnosis, N








KPS, Karnofsky performance scale; 3D-CRT, 3D-Conformal radiation therapy;
IMRT, Intensity modulated radiation therapy.pneumonitis. This series was subsequently updated by
Liu et al. with a larger number of patients focusing on
identifying risk factors for radiation pneumonitis [17]. In
a smaller series employing a number of different frac-
tionation schemes, Trakul et al. described inferior out-
comes in 15 patients with 1-year local control of 65.5%,
but with minimal toxicity [18]. Here we review our insti-
tutional experience using SBRT in 39 patients who had
received prior fractionated RT with emphasis on predict-
ive factors for clinical outcomes and toxicity.
Methods
After obtaining IRB approval for retrospective review of
data in our institutional database, we identified all pa-
tients with a prior history of conventionally fractionated
RT to the thorax who underwent hypofractionated re-
irradiation with SBRT at Memorial Sloan-Kettering Can-
cer Center (MSKCC) from 11/2004 to 7/2011 (Table 1).
Patients with prior RT to the breast were excluded.
Thirty-nine patients met the inclusion criteria and their
records were reviewed for patient and disease character-
istics, prior fractionated RT dosimetric variables, SBRT
dosimetric variables, length of time from the end of
SBRT to local and regional relapse, length of survival,
and toxicity.
Previous RT variables reviewed included dates of ther-
apy, prescription dose, graphic dose distributions, plan-
ning target volume (PTV) size, location and coverage,
mean lung doses and V20 for the ipsilateral and total
lungs. Complete previous RT records were available for
22 patients who received either three-dimensional con-
formal radiotherapy (3D-CRT) or intensity-modulated
radiotherapy (IMRT) at MSKCC (n = 21) or an outside
institution (n = 1). Seven patients treated at MSKCC and
2 at outside institutions received two-dimensional treat-
ments, typically AP-PA and off-cord boost fields. To ob-
tain dosimetric information for these 9 patients, their
plans were reconstructed using prior portal images and
current computed tomography (CT) scans.
For SBRT planning, a four-dimensional (4D) CT simu-
lation scan was performed with the patient immobilized
in a custom-designed Alpha CradleW device. The in-
ternal target volume was delineated by combining gross
tumor volume projections from each breathing phase of
the 4D scan. A 2-3 mm expansion was used to create a
clinical target volume, and a 5 mm expansion was used
to create a PTV. SBRT treatment plans were generated
using an in-house treatment planning system [19,20] to
deliver the prescribed dose to the PTV using IMRT. The
dose was prescribed to the isodose line covering the
PTV (generally 100% isodose line). Patients were treated
using multi-field coplanar beam arrangements typically
consisting of 4–6 beams. The degree of overlap between
the previous conventionally fractionated treatment and
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image registration between old and new planning scans.
Risk-adapted SBRT fractionation schemes were based on
PTV size and degree of overlap between areas from con-
ventionally fractionated RT and SBRT (Table 2). Pre-
scription BED10 ≤ 60 Gy was more frequently considered
for cases with PTV volumes > 70 cc and/or complete
overlap. SBRT dosimetric parameters analyzed included
PTV size, coverage, mean dose to ipsilateral lung, mean
dose to both lungs, volume receiving 20 Gy (V20) of ip-
silateral lung and V20 of both lungs. Mean lung doses
were calculated based on the total lung volume minus
GTV. To estimate composite mean lung doses from
fractionated RT and SBRT, the SBRT mean dose was
converted to 2 Gy equivalents using the linear-quadratic
model (α/β = 3 Gy) and added to the total mean dose of
the first course of fractionated RT.
Patients were clinically evaluated approximately 1
month after completion of SBRT and every 3–6 months
thereafter with clinical exams and chest CT scans.
The primary endpoints were local progression-free
survival (LPFS) and toxicity. LPFS was defined as the
time from the end of SBRT until the date of local pro-
gression or last clinic visit if the patient did not progress.
Local progression was defined as an enlarging mass in
the SBRT treatment field and was confirmed by PET
(6 of 10 cases with local progression) and biopsy
(4 cases), if feasible. Pulmonary toxicity, including dys-
pnea, hypoxia, cough and pneumonitis, was graded
according to CTCAE v4.0. For analysis of factors associ-
ated with pulmonary toxicity, a binary toxicity endpointTable 2 SBRT characteristics
SBRT Characteristics Total
N = 39
Median BED10 , Gy (range) 70 (43–180
BED10≥ 100 Gy, N (%) 15 (38)
60 Gy in 3 fr (BED10 = 180 Gy) 3
54 Gy in 3 fr ( BED10 = 151 Gy) 4
48 Gy in 4 fr ( BED10 = 106 Gy) 8
BED10 < 100 Gy, N (%) 24 (62)
40-45 Gy in 5 fr ( BED10 = 72-86 Gy) 4
20-22 Gy in 1 fr ( BED10 = 60-70 Gy) 4
32-35 Gy in 4–5 fr ( BED10 = 54-59 Gy) 4
27.5-30 Gy in 5 fr ( BED10 = 43-48 Gy) 12
Median PTV size, cm3 (range) 67 (17–473
Median GTV size, cm3 (range) 19 (0.7-227
Median ipsilateral lung mean dose, Gy (range) 6.3 (1.7-13.1
Median combined lung mean dose, Gy (range) 3.2 (0.8-7.2)
Median ipsilateral lung V20, % (range) 10 (2–30)
Median combined lung V20, % (range) 5 (1–12)
BED10, Biologically equivalent dose for α/β = 10; PTV, Planning treatment volume; GTwas defined as pulmonary toxicity within 6 months. Six
of 39 patients in the study group who did not develop
toxicity and had follow-up of less than 6 months were
excluded. Secondary endpoints were recurrence-free sur-
vival (RFS) and overall survival (OS). Actuarial LPFS,
RFS and OS from the date of SBRT were estimated with
the Kaplan-Meier method. Cox regression models were
used to evaluate prognostic factors for each of the end-
points. Cut points used for continuous variables in this
analysis were based on clinical relevance (BED10) or di-
chotomized at the approximate median (time from con-
ventionally fractionated RT to SBRT, KPS, and PTV
size). Multivariable analysis was precluded by the small
number of events. Fisher’s exact and Wilcoxon rank sum
tests were used to evaluate the association between risk
of toxicity and RT parameters.
Results
Patient and tumor characteristics
At the time of SBRT, the median patient age was 71
years (range 41–94 years) and the median Karnofsky
Performance Score (KPS) was 80 (range 60–100)
(Table 1). Twenty-two patients (56%) had documented
chronic obstructive pulmonary disease. Seventeen pa-
tients received SBRT for a metachronous primary lung
cancer, 18 for recurrent lung cancer, and 4 for metasta-
ses from other histologies. The criteria used for classify-
ing tumors as a second primary rather than a recurrence
included different histology, time interval between can-
cers of at least two years, and location within different
lobes in the absence of tumor in the lymphatics [21].Overlap with prior RT No overlap
N = 22 N = 17
) 48 (43–106) 106 (58–180)
4 (18) 11 (65)
18 (82) 6 (35)
) 117 (20–473) 45 (17–197)
) 43 (2–227) 6 (0.7-74)
) 4.8 (1.7-13.1) 6.6 (1.7-13.1)
3.1 (1.1-6.2) 4.3 (0.8-7.2)
10 (2–30) 12 (3–25)
5 (1–10) 5 (2–12)
V, Gross tumor volume; V20, Percent of volume receiving 20 Gy or more.
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Thirty-eight patients received one prior course of fraction-
ated RT to the thorax with a median prescription dose of
61 Gy (range, 30–80 Gy) (Table 2). One patient received
two prior courses of fractionated RT (74 Gy and 56.7 Gy)
to the ipsilateral lung. The indications for prior RT included
definitive therapy for NSCLC (n = 30), SCLC (n = 6), and
esophageal cancer (n = 2), adjuvant post-operative therapy
for NSCLC (n = 4) and mesothelioma (n = 1), and palliation
(n = 5). Fractionated RT was delivered using conventional
two-dimensional technique (n = 13), 3D-CRT (n = 12), and
IMRT (n = 14). The median interval between fractionated
thoracic RT and SBRT was 37 months (range 1–180
months). Two patients had planned conventionally frac-
tionated RT and SBRT within a short interval for oligo-
metastatic disease and synchronous primaries (1 and 5
months, respectively).
SBRT characteristics
A variety of risk-adapted SBRT fractionation schemes were
used with a median BED10 of 70.4 Gy (range 42.6-180 Gy)
(Table 2). Twenty-two patients had overlap of the high-
dose region defined as ≥ 50% isodose lines (IDL) of the
SBRT field with the prior fractionated RT field. SBRT pre-
scription doses in patients with overlap between the treat-
ment fields were lower than in patients without overlap
(median BED10 = 48 Gy vs. 106 Gy). The median PTV
treated with SBRT was 67 cc (range 17–473 cc). The me-
dian PTV for 22 patients with overlap was 117 cc (range
20–473 cc), while the median PTV of 17 patients with less
or no overlap was 45 cc (range 17–197 cc). Fifteen patients
(38%) received doses with prescription BED10 above 100
Gy. Of these, four had overlap of the high-dose region of
the SBRT field with the prior conventionally fractionated
RT field. Dosimetric parameters including V20 and mean
lung doses for ipsilateral or both lungs are listed in Table 2.
Local control and survival
With a median follow up of 12.6 months (range 1.3-47.5
months), the actuarial LPFS was 77% at 1 year and 64% at 2
years (Figure 1). The actuarial median LPFS was not
reached, whereas median RFS and OS were 13.8 and 22.0
months, respectively. On univariate analysis, no overlap
with the prior RT field (hazard ratio [HR] = 0.11, p = 0.04),
BED10 of ≥100 Gy (HR = 0.18, p = 0.04), time interval of >
36 months between conventionally fractionated RT and
SBRT (HR= 0.25, p = 0.05), PTV < 75 cc (HR = 0.09,
p = 0.03) and KPS ≥ 80 (HR = 0.16, p = 0.03) were associated
with longer LPFS (Table 3). Having a metachronous pri-
mary lung cancer was borderline significant for a higher
LPFS (p = 0.06).
Similarly, longer RFS and OS were associated with the
diagnosis of a second primary cancer (HR = 0.16, p = 0.002
and HR = 0.37, p = 0.05, respectively), BED10 of ≥100 Gy(HR = 0.31, p = 0.038 and HR = 0.25, p = 0.014, respect-
ively), and PTV volume <75 cc (HR = 0.30, p = 0.03 and
HR = 0.27, p = 0.008, respectively. In addition, KPS of ≥80
was associated with longer OS (HR = 0.11, p = 0.0003).
Multivariate analysis was precluded by the limited num-
ber of patients and events in the dataset.
Toxicity
Grade 2 and 3 pulmonary toxicity, including dyspnea, hyp-
oxia, cough and pneumonitis, were observed in 7 and 2 pa-
tients, respectively at a median of 3.0 months (range 1–6
months) (Table 4). Grade 2 pulmonary symptoms resolved
in 2 of 6 patients for whom further follow-up was available,
and continued to be reported by 4 patients, including 2
with poorly controlled COPD, 1 patient with hemoptysis
due to disease progression, and 1 patient who developed a
malignant pleural effusion shortly after undergoing SBRT.
Patients who developed grade 3 toxicity continued to be
oxygen-dependent at 23 and 6 months of follow-up. There
was no clear correlation of any examined dosimetric
variables with pulmonary toxicity. When patients with
grade <2 and ≥2 pulmonary toxicity were compared, there
were no statistically significant differences in V20 of prior
fractionated RT or SBRT to the ipsilateral lung or total
lungs. Similarly, there was no difference in mean dose,
whether prior fractionated treatment and SBRT were con-
sidered separately, or as a composite of both treatments to-
gether (data not shown). SBRT doses with a BED10 ≥100
Gy vs. <100Gy and overlap of prior conventionally frac-
tionated RT field with SBRT field were also not predictive
of pulmonary toxicity. Of note, 4 of 22 patients with overlap
of conventionally fractionated RT field with SBRT field re-
ceived doses with BED10 ≥ 100Gy (48 Gy in 4 fractions).
Only one of these patients developed grade 2 dyspnea, and
none developed grade 3 or higher pulmonary events.
Other grade 2 or higher toxicities included chest wall
pain in 7 patients (18%), fatigue in 6 patients (15%) and
skin/connective tissue toxicity in 2 patients (5%). There
were no grade 2 or higher brachial plexopathy or esopha-
geal toxicity. With the exception of one patient with grade
4 skin toxicity [22], no grade 4 or 5 events were observed.
Discussion
Patients with a history of a primary lung cancer or pul-
monary metastases are at a significant risk of developing
other malignant lung lesions that may benefit from aggres-
sive local treatment. Their therapeutic options are often
limited, and RT represents an important modality in this
setting. Image-guided hypofractionated stereotactic body
radiation therapy (SBRT) is particularly useful and effective
for small lung lesions.
Here we describe a cohort of patients with a history of
conventionally fractionated thoracic RT who received
SBRT using a variety of fractionation schemes. In the
Figure 1 Kaplan-Meier analyses of LPFS, RFS and OS. LPFS (A),
RFS (B) and OS (C) were calculated from the end of SBRT. Number
at risk is displayed below each graph.
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with SBRT consistently exceed 90% [12,23-26]. Importantly,
doses with a BED10 ≥100Gy delivered to the isocenter have
been reported to be associated with improved LC and sur-
vival [11]. Similarly, in the setting of previously un-irradiated lungs, SBRT for pulmonary metastases leads to
high rates of LC up to 95- 96% at two years when high
BED10 regimens are used [13,27]. However, in the setting of
re-irradiation, concerns for increased toxicity frequently
limit the radiation doses used with SBRT. Consistent with
previously published single institution series [16-18], we
show that acceptable rates of LC can be achieved with
SBRT in this setting. One possible reason that our LC
(2-year LC 64%) is lower than that reported by Kelly et al.
(2-year LC 92%) may be related to our risk-adapted ap-
proach of selecting fractionation schemes with lower
BED10 for patients with direct overlap between the high-
dose regions of SBRT and the prior conventionally fraction-
ated fields. Nevertheless, the local progression-free rate at 1
and 2 years in our study (77% and 64%, respectively) com-
pare favorably with historical results of conventionally
fractionated re-irradiation (51% and 42%, respectively) [6]
or 1-year results of SBRT experience reported by Trakul
et al. (65.5%). The OS reported here (median survival 22.0
months) is superior to that achieved with conventional re-
irradiation in a similar group of 18 patients treated with
definitive intent (median survival 15 months) [8] and is
similar to that in other SBRT re-irradiation series (esti-
mated median survival 21–26 months) [16,18].
Factors that would predict for a favorable outcome in the
setting of re-irradiation are largely unknown, but may be
clinically useful in selecting best candidates for re-irra-
diation or in deciding on the appropriate SBRT dose. We
found that in select patients with previously irradiated
lungs, doses of BED10 ≥100 Gy may be feasible and associ-
ated with good LPFS, RFS and OS without an unacceptably
high risk of toxicity. In addition to BED10, other factors as-
sociated with improved LPFS on univariate analysis include
receiving treatment for recurrent vs. metachronous pri-
mary lung cancer (typically early-stage), no overlap with
prior RT, longer interval from prior RT to SBRT and
smaller PTV volume. The type of lesion (recurrent vs.
metachronous), overlap with prior RT, interval from prior
RT to SBRT and PTV volume also correlate with RFS,
whereas the type of lesion, PTV volume and KPS correlate
with OS. Some of these factors are likely interrelated, and
some may be more important than others in predicting
outcomes, but multivariate analysis was precluded by the
small number of events in this study. A larger cohort is
needed to determine the relative importance of these po-
tential prognostic factors.
Similar to the series reported by Trakul et al., we ob-
served a low rate of grade 3 or higher pulmonary toxi-
city of 5% [18]. In contrast, the original and updated
MDAnderson reports described a 28% and 20.8% incidence
of grade 3 or higher radiation pneumonitis, respectively
[16,17]. Some of these differences are likely related to dif-
ferences in dose schedules used. While 72-100% of patients
in the two MD Anderson series were treated with 50Gy in
Table 3 Factors associated with LPFS, RFS and OS on univariate analysis
LPFS RFS OS
Characteristic HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Type of Cancer
Recurrent/metastasis Reference Reference Reference
Second Primary 0.26 (0.07, 1.04) 0.06 0.16 (0.05, 0.51) 0.002 0.37 (0.14, 0.99) 0.05
Overlap with prior RT field
Yes Reference Reference Reference
No 0.11 ( 0.01,0.88) 0.04 0.52 (0.19, 1.39) 0.19 0.69 (0.27, 1.77) 0.44
BED10 of SBRT
<100 Gy Reference Reference Reference
≥100 Gy 0.18 (0.04, 0.90) 0.04 0.31 (0.10, 0.93) 0.038 0.25 (0.08, 0.76) 0.014
Time from prior RT to SBRT
≤36 months Reference Reference Reference
>36 months 0.25 (0.06,0.99) 0.05 0.37 (0.14, 0.97) 0.04 0.63 (0.25, 1.56) 0.32
PTV volume
>75 cc Reference Reference Reference
16-75 cc 0.09 (0.01,0.79) 0.03 0.30 (0.10, 0.90) 0.03 0.27 (0.10, 0.71) 0.008
KPS
<80 Reference Reference Reference
≥80 0.16 (0.03, 0.85) 0.03 0.43 (0.10, 1.95) 0.28 0.11 (0.03, 0.36) 0.0003
BED10, Biologically equivalent dose for α/β = 10; PTV, Planning treatment volume; KPS, Karnofsky performance scale.
Reyngold et al. Radiation Oncology 2013, 8:99 Page 6 of 7
http://www.ro-journal.com/content/8/1/994 fractions (BED10 > 100 Gy), 62% of patients in our cohort
received fractionation schemes with lower effective doses
(BED10 < 100 Gy), chosen at the discretion of the treating
physician, with the aim of limiting toxicity. In addition, the
median interval between fractionated RT and SBRT was
longer in our study (37 months vs. 21–22 months) which
may, at least in part, contribute to the observed difference.
Liu et al. have identified a number of risk factors for se-
vere pneumonitis, including ECOG status, FEV1, V20 of
the composite plan and presence or absence of overlapTable 4 Grade ≥ 2 toxicities (CTCAE v4.0)
Grade ≥ 2 Toxicity (CTCAE 4.0) N (%)
Pulmonary (dyspnea, hypoxia, cough, pneumonitis) 9 (23%)
Grade 2 7
Grade 3 2






Skin/soft tissue 2 (5%)
Grade 2 1
Grade 3 0
Grade 4 1with prior RT [17]. Despite evaluating a number of similar
clinical and dosimetric parameters, we were unable to
identify patient or treatment factors that may help predict
which patients are at increased risk of developing toxicity
in our cohort. This is likely related to the overall low num-
ber of toxic events. Taken together these studies suggest
that for patients at very high risk for radiation pneumonitis
according to the MD Anderson criteria, alternative frac-
tionation schemes with lower BED10 may be considered.
Further studies are necessary to better define the risk-
benefit ratios of different fractionation schemes.
Conclusion
SBRT can be used for re-treatment of previously irradiated
lung. Consistent with data in the primary setting, fraction-
ation schemes with BED10 ≥ 100 Gy appear to have more
durable responses in the setting of re-irradiation on univar-
iate analysis. Treatment toxicity may be reduced by using a
risk-adapted approach with lower BED10 for lesions with
direct overlap with the previously irradiated field. Further
studies to address the risk-benefit ratios of different SBRT
fractionation schemes in the context of previously irradi-
ated lung are warranted.
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